

## LRRC8A Antibody(C-term)

Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP19519b

## **Specification**

## LRRC8A Antibody(C-term) - Product Information

Application WB,E
Primary Accession OSIWT6

Other Accession <u>Q4V817</u>, <u>Q80WG5</u>, <u>NP\_062540.2</u>

Reactivity Human, Mouse

Predicted Rat
Host Rabbit
Clonality Polyclonal
Isotype Rabbit IgG
Antigen Region 782-810

## LRRC8A Antibody(C-term) - Additional Information

#### **Gene ID 56262**

#### **Other Names**

Volume-regulated anion channel subunit LRRC8A, Leucine-rich repeat-containing protein 8A, Swelling protein 1, LRRC8A, KIAA1437, LRRC8, SWELL1

## Target/Specificity

This LRRC8A antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 782-810 amino acids from the C-terminal region of human LRRC8A.

## **Dilution**

WB~~1:1000

## **Format**

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

### **Storage**

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

## **Precautions**

LRRC8A Antibody(C-term) is for research use only and not for use in diagnostic or therapeutic procedures.

## LRRC8A Antibody(C-term) - Protein Information

Name LRRC8A {ECO:0000303|PubMed:22532330, ECO:0000312|HGNC:HGNC:19027}

Function Essential component of the volume-regulated anion channel (VRAC, also named VSOAC



channel), an anion channel required to maintain a constant cell volume in response to extracellular or intracellular osmotic changes (PubMed: 24725410, PubMed: 29769723, PubMed:24790029, PubMed:26530471, PubMed:26824658, PubMed:28193731). The VRAC channel conducts iodide better than chloride and can also conduct organic osmolytes like taurine (PubMed: <u>24725410</u>, PubMed: <u>30095067</u>, PubMed: <u>24790029</u>, PubMed: <u>26530471</u>, PubMed: 26824658, PubMed: 28193731). Mediates efflux of amino acids, such as aspartate and glutamate, in response to osmotic stress (PubMed: 28193731). LRRC8A and LRRC8D are required for the uptake of the drug cisplatin (PubMed: 26530471). In complex with LRRC8C or LRRC8E, acts as a transporter of immunoreactive cyclic dinucleotide GMP-AMP (2'-3'-cGAMP), an immune messenger produced in response to DNA virus in the cytosol: mediates both import and export of 2'-3'-cGAMP, thereby promoting transfer of 2'-3'-cGAMP to bystander cells (PubMed: 33171122). In contrast, complexes containing LRRC8D inhibit transport of 2'-3'-cGAMP (PubMed:33171122). Required for in vivo channel activity, together with at least one other family member (LRRC8B, LRRC8C, LRRC8D or LRRC8E); channel characteristics depend on the precise subunit composition (PubMed: <u>24790029</u>, PubMed: <u>26824658</u>, PubMed: <u>28193731</u>). Can form functional channels by itself (in vitro) (PubMed: 26824658). Involved in B-cell development: required for the pro-B cell to pre-B cell transition (PubMed: 14660746). Also required for T-cell development (By similarity). Required for myoblast differentiation: VRAC activity promotes membrane hyperpolarization and regulates insulin-stimulated glucose metabolism and oxygen consumption (By similarity). Also acts as a regulator of glucose-sensing in pancreatic beta cells: VRAC currents, generated in response to hypotonicity- or glucose-induced beta cell swelling, depolarize cells, thereby causing electrical excitation, leading to increase glucose sensitivity and insulin secretion (PubMed: 29371604). Also plays a role in lysosome homeostasis by forming functional lysosomal VRAC channels in response to low cytoplasmic ionic strength condition: lysosomal VRAC channels are necessary for the formation of large lysosome-derived vacuoles, which store and then expel excess water to maintain cytosolic water homeostasis (PubMed:31270356, PubMed:33139539).

#### **Cellular Location**

Cell membrane; Multi-pass membrane protein. Lysosome membrane; Multi-pass membrane protein. Note=Mainly localizes to the cell membrane, with some intracellular localization to lysosomes

## **Tissue Location**

Expressed in brain, kidney, ovary, lung, liver, heart, and fetal brain and liver. Found at high levels in bone marrow; lower levels are detected in peripheral blood cells. Expressed on T- cells as well as on B-lineage cells.


#### LRRC8A Antibody(C-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- <u>Immunofluorescence</u>
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

## LRRC8A Antibody(C-term) - Images





All lanes: Anti-LRRC8A Antibody (C-term) at 1:2000 dilution Lane 1: 293T/17 whole cell lysate Lane 2: mouse kidney lysate Lysates/proteins at 20  $\mu$ g per lane. Secondary Goat Anti-Rabbit lgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size: 94 kDa Blocking/Dilution buffer: 5% NFDM/TBST.




LRRC8A Antibody (C-term) (Cat. #AP19519b) western blot analysis in 293 cell line lysates (35ug/lane). This demonstrates the LRRC8A antibody detected the LRRC8A protein (arrow).

## LRRC8A Antibody(C-term) - Background

This gene encodes a protein belonging to the leucine-rich repeat family of proteins, which are involved in diverse biological processes, including cell adhesion, cellular trafficking, and hormone-receptor interactions. This family member is a putative four-pass transmembrane protein that plays a role in B cell development. Defects in this gene cause autosomal dominant non-Bruton type agammaglobulinemia, an immunodeficiency disease resulting from defects in B cell maturation. Multiple alternatively spliced transcript variants, which encode the same protein, have been identified for this gene.

# LRRC8A Antibody(C-term) - References

Olsen, J.V., et al. Cell 127(3):635-648(2006) Smits, G., et al. Mol. Immunol. 41(5):561-562(2004)





Kubota, K., et al. FEBS Lett. 564 (1-2), 147-152 (2004) : Sawada, A., et al. J. Clin. Invest. 112(11):1707-1713(2003) Conley, M.E. J. Clin. Invest. 112(11):1636-1638(2003)